New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint ...

Verastem doses first patient in TARGET-D 202, a registration-directed Phase 2 clinical trial of VS-7375 in KRAS G12D-mutated ...

Researchers at Dana-Farber Cancer Institute have uncovered why small cell lung cancer (SCLC) can stay largely out of reach of the immune system, even when the cancer cells themselves are vulnerable to ...

Alveltamig is a trispecific T-cell engager, enhancing immune response by linking T cells to cancer cells with three binding arms. The trial addresses treatment challenges for small cell lung cancer ...

T cell engagers, including Imdelltra, show promise in small cell lung cancer, outperforming chemotherapy in trials and changing the standard of care. Antibody-drug conjugates like I-DXd and ABBV-706 ...

Summit said it has already shared the latest safety data with the U.S. Food and Drug Administration.

Researchers are applying evolutionary theory to cancer by changing treatments before tumours have time to develop resistance.

Lung cancer remains the leading cause of cancer-related mortality worldwide. Although small cell lung cancer (SCLC) accounts for a smaller percentage of lung cancer cases, it has remained a ...

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer progression and its ability to evolve resistance to treatment. Targeting ...